Gonadorelin

What gonadorelin is and how it works

Gonadorelin is synthetic gonadotropin-releasing hormone: a ten-amino-acid peptide with the same structure as the hypothalamic hormone that governs the reproductive axis. It is not an analog of that hormone. It is a replicate of it, which is why the anti-doping authorities that name it write the two names together as one entry. Given to the pituitary in the right pattern, it triggers release of luteinizing hormone and follicle-stimulating hormone, which in turn act on the testis or the ovary. Everything interesting about the compound follows from the word pattern.

The experiment that established this is old, decisive, and was done in monkeys. In rhesus monkeys whose hypothalamic lesions had abolished pituitary gonadotropin release, constant infusion of gonadotropin-releasing hormone failed to restore sustained gonadotropin secretion, while intermittent administration once per hour — the physiological frequency in those animals — reestablished it. The authors were explicit that the effect was attributable to the pattern of delivery rather than to the amount the pituitary was exposed to, and that switching a restored animal to continuous administration produced what they called desensitization or down regulation.^[1] That single result explains both why every therapeutic regimen for this compound in the human literature runs through a portable pump, and why a drug that stimulates the axis in pulses suppresses it when given continuously.

The pharmacokinetics reinforce the point. In six women drawn from a group of 14 with anovulatory infertility, measured after 5, 10 and 20 microgram injections, peak circulating concentrations were reached 5 to 10 minutes after a subcutaneous injection and within 2 minutes after an intravenous one, with intravenous peaks 3.6 to 6.3 times higher and the sums of increments 2.0 to 3.9 times greater.^[2] This is a very short-acting molecule. No human plasma half-life figure is quoted on this page, because none was verified from a primary source at authoring time.

Draw the family boundary before reading a single result, because on this axis the neighbours are numerous and several of them do the opposite thing. Gonadorelin is the parent hormone, and the monkey experiment above is a result about the parent hormone delivered continuously rather than about any of the molecules below.^[1] The gonadotropin-releasing hormone agonist analogs — buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin, triptorelin — are different molecules, engineered for a long duration of action, and they are given clinically to suppress the axis rather than to drive it. That is the opposite clinical intent, it is the basis of a very large approved oncology and paediatric literature, and none of it transfers in either direction. The antagonists — cetrorelix, ganirelix, degarelix, elagolix — block the receptor outright and are different again. Human chorionic gonadotropin acts one tier lower, directly at the luteinizing hormone receptor on the Leydig cell, and clomiphene and enclomiphene act on oestrogen receptors; all three appear in the same online discussions as gonadorelin and none of them is gonadorelin. Every result sentence below names the molecule that was actually administered.

What the research actually shows

Men with congenital hypogonadotropic hypogonadism — the largest body of evidence, and almost none of it randomized. A systematic review and meta-analysis pooling seven comparative studies and 420 men reported pulsatile gonadotropin-releasing hormone therapy associated with a larger testicular volume, standardized mean difference −1.43, P = 0.01, and earlier spermatogenesis, weighted mean difference −5.30 months, P = 0.004, against combined gonadotropin therapy. The same analysis found the differences in positive sperm-detection rate, P = 0.08, sperm concentration, P = 0.37, and pregnancy rate, P = 0.11, not significant, and its authors closed by saying high-quality randomized controlled trials are needed.^[3] The largest single comparison since — a retrospective cohort of 155 post-pubertal men, which PubMed types as a clinical trial while the paper itself describes a single-centre retrospective design — reported no difference in the rate of successfully inducing spermatogenesis, 82.1% against 75.8%, P = 0.356, alongside a shorter mean time to success, 12.34 against 14.74 months, P = 0.038, and a greater end-of-treatment testicular volume, 15 against 12 mL, P = 0.010.^[4] A 202-man retrospective cohort found the median time to first sperm 6 months against 18, P less than 0.001, and — the half that is easy to drop — lower serum testosterone during follow-up in the pulsatile group, 8.3 ± 4.6 against 16.2 ± 8.2 nmol/L, P less than 0.001.^[5]

The oldest comparison in this set is the least flattering and belongs on the page for that reason. Eight men who had already achieved maximal testicular growth and function on human chorionic gonadotropin and human menopausal gonadotropin were switched to pulsatile subcutaneous gonadotropin-releasing hormone. Only four normalized plasma testosterone. Testicular size in those four rose a further 53%, P less than 0.01 — and two men who had been azoospermic on gonadotropins remained azoospermic, while sperm counts in the other two rose minimally. The authors concluded that pulsatile gonadotropin levels are more effective at stimulating testicular growth but not necessarily sperm output.^[6] A 2015 study of 34 adolescent boys is titled as though pulsatile therapy is superior to human chorionic gonadotropin; its own results section reports that both groups showed significantly increased penile length and testosterone and that the difference between the two groups was not statistically significant, with larger testes in the pulsatile group. Two published Comments dispute the title. The numbers, not the title, are what this page reports.^[7]

Women with hypothalamic amenorrhoea — the only claim area here with randomized trials, and they randomized the pattern. Twenty women treated over 41 cycles at a fixed 20 nanograms per kilogram per pulse were randomly assigned to pulse intervals of 60, 90, 120 or 180 minutes; ovulation occurred in 60% of cycles at 90 minutes and 88% at 120 minutes, against 12% and 38% at the extremes, P ≤ 0.05.^[12] A second randomized study assigned 15 women to 5, 10 or 20 micrograms per pulse and reported significantly more anovulation in the 5-microgram cycles.^[13] A systematic review and meta-analysis of 35 studies and 1,002 women — only three of them randomized — reported high ovulation rates, ovarian hyperstimulation syndrome that is low in incidence and mild in severity, multiple-gestation rates that are low but slightly higher than the general population, and subcutaneous administration achieving ovulation rates comparable to intravenous.^[10] That last finding sits in tension with the 1984 pharmacokinetic study, in which subcutaneous courses produced ovulation in only one of four women while intravenous courses were ovulatory in 16 of 20 treatments; the meta-analysis is the current position and the older study explains why route was ever thought to matter.^[2] A 25-year single-centre cohort of 66 women across 212 cycles reported a live birth rate of 65.9% per treatment, monofollicular ovulation in 75% of cycles and a single dizygotic twin pregnancy at 1.6%; two of its authors disclose consulting or speaking relationships with a pharmaceutical company.^[11]

The diagnostic test — the original US approved use, still performed. A single 100 microgram intravenous bolus produced marked rises in both gonadotropins in 67 men, P less than 0.0001 for the linear trend, with peak luteinizing hormone differing by FSHB-211 genotype, P = 0.012, while the genotype main effect on follicle-stimulating hormone did not reach significance, P = 0.9502 and P = 0.8576; the authors say their results should be interpreted with caution.^[14] A separate study of 91 patients with idiopathic hypogonadotropic hypogonadism, 27 with constitutional delay of growth and puberty, 6 prepubertal children and 20 pubertal adults derived a peak luteinizing hormone cutoff below 9.74 IU/L with 80.0% sensitivity and 86.4% specificity in males, and concluded the test is almost sufficient to discriminate the two diagnoses in males but unnecessary in females.^[15]

Where the evidence is weak

The question that brings most readers here has no published study behind it. The men in the published therapeutic literature have congenital hypogonadotropic hypogonadism: they produce no gonadotropin-releasing hormone of their own, and the pump is supplying a pituitary with a signal it has never received.^[3][4] A man on exogenous testosterone has an intact hypothalamus that is being suppressed by negative feedback. That second case is a different starting physiology, and the record on it is empty. A PubMed search for the query gonadorelin[tiab] AND ("men"[tiab] OR "male"[tiab]) AND "hypogonadism"[tiab] AND ("testosterone therapy"[tiab] OR "TRT"[tiab]) on 1 September 2026 returned 0 records. A search for the query gonadorelin[tiab] AND "fertility preservation"[tiab] on the same date returned 0 records. A search for the query gonadorelin[tiab] AND ("testosterone replacement"[tiab] OR "testosterone therapy"[tiab] OR "androgen replacement"[tiab]) returned 2 records — a genetics follow-up study in congenital hypogonadotropic hypogonadism and an in-vitro study of sex hormone-binding globulin — and a search for the query "pulsatile GnRH"[tiab] AND ("testosterone therapy"[tiab] OR "testosterone replacement"[tiab]) returned 7 records, none of them a study of gonadorelin given alongside testosterone therapy. This is not a negative trial. There is no trial. What does return results is the same query shape asked about a different molecule: a same-session control search for (hCG[tiab] OR "human chorionic gonadotropin"[tiab]) AND ("testosterone replacement"[tiab] OR "testosterone therapy"[tiab]) AND (spermatogenesis[tiab] OR "intratesticular testosterone"[tiab] OR fertility[tiab]) returned 53 records on 1 September 2026 — which confirms the search works and confirms that the literature readers have encountered is about human chorionic gonadotropin, an agonist at the luteinizing hormone receptor one tier further down the axis. Whatever that literature shows is a fact about that molecule and is not carried across to this page. It is also the reason the compound-level evidence grade at the top of this page reads lower than several of the individual claim grades below it: the grade follows the claim a reader typically arrives with, and that claim has no human evidence at all.

The studied intervention and the marketed one are not the same thing. Every therapeutic regimen in this literature is a portable pump delivering a small amount every 90 minutes, continuously, for months. That is the intervention the monkey experiment predicts will work and the only one the human studies tested.^[1] A once-daily or every-other-day injection is a different delivery pattern, and the same experiment is the reason to expect it to behave differently. No published administered amount exists for that pattern: a PubMed search for the query gonadorelin[tiab] AND "subcutaneous"[tiab] AND ("adult"[tiab] OR "adults"[tiab]) AND "daily"[tiab] on 1 September 2026 returned 0 records.

The design ceiling is low and the provenance is narrow. Outside ovulation induction, essentially every comparative human study of pulsatile gonadotropin-releasing hormone therapy is retrospective or otherwise non-randomized; the meta-analysis in men closes by calling for high-quality randomized trials.^[3] The men's comparative literature is also geographically narrow: the pooled analysis, the 155-man cohort, the 202-man cohort, the 45-man series and the adolescent study were all conducted at tertiary centres in China, one of them with co-authors at a US academic hospital.^[4][5][8][7] On disclosures, applied to every source doing the same job: the 25-year ovulation cohort names two authors with industry consulting or speaking relationships; the PubMed records for the pooled amenorrhoea analysis and the two randomized pulse studies carry no conflict-of-interest statement, the latter two predating routine ones; and the pooled analysis in men states that its authors have nothing to disclose.^{[11][10][12][13][3]}

Nothing in the record speaks to sexual function, body composition or long-term use. A PubMed search for the query gonadorelin[tiab] AND ("libido"[tiab] OR "erectile"[tiab] OR "sexual function"[tiab]) on 1 September 2026 returned 4 records, three of which are reviews of the agonist analogs and one of which concerns androgen-deprivation therapy for prostate cancer — no sexual-function outcome data for gonadorelin itself. A search for the query gonadorelin[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "muscle"[tiab]) on the same date returned 2 records, neither reporting a body-composition outcome of gonadorelin. A search for the query gonadorelin[tiab] AND ("long-term safety"[tiab] OR "long term safety"[tiab]) returned 0 records, against a same-session control search for leuprolide[tiab] AND ("long-term safety"[tiab] OR "long term safety"[tiab]) returning 7. And a search of ClinicalTrials.gov on 1 September 2026 for the intervention "pulsatile GnRH" returned 11 studies, none of them a trial of gonadorelin given alongside testosterone therapy.

Adverse events are counted in small single-arm series. The best available frequency figures come from one retrospective series of 45 men — gynecomastia in 8, subcutaneous induration in 6, allergic reaction in 3 — which is a count in one centre rather than an incidence.^[8] The most serious published event, anaphylaxis within three minutes of an intravenous diagnostic dose, is a single case report and is described here as one.^[9]

Legal and regulatory status

Gonadorelin is not currently an FDA-approved human drug, and the reason is specific to this compound. Two US human applications exist and every product on both is discontinued. NDA 018123, FACTREL, gonadorelin hydrochloride, held by Hikma, was approved on September 30, 1982 in three vial strengths. NDA 019687, LUTREPULSE KIT, gonadorelin acetate, held by Ferring, was approved on October 10, 1989 in two vial strengths. All five products carry a marketing status of Discontinued, there are no abbreviated applications, and no current approved labeling for a human gonadorelin product exists in FDA's labeling records.

The approvals were never withdrawn. A search of the Federal Register across nine query shapes — the substance name, both salt names, both brand names, both application numbers, and the substance name filtered to FDA notices — returned no withdrawal-of-approval notice and no safety-or-effectiveness determination for either application; the same searches run in the same session against a compound whose approvals were withdrawn returned both its withdrawal notice and its subsequent determination, so the null is a real absence rather than a failed search. The Orange Book corroborates it: products FDA has formally determined were not withdrawn for safety or effectiveness reasons carry a specific annotation on their discontinued rows, and gonadorelin's five discontinued rows carry no such annotation, because no such determination was ever made. The honest statement is therefore narrow: both approvals were discontinued by their sponsors and the products moved to the discontinued list, the approvals themselves were never withdrawn, and FDA has never made a finding either way about the safety or effectiveness of either product. "FDA withdrew approval of gonadorelin" would be false.

What exists in the United States today is compounded gonadorelin, dispensed on a prescription. That is a regulatory description and nothing more. The national drug code directory lists 13 gonadorelin registrations and every one of them is an active-ingredient registration rather than a finished drug product — twelve registered as bulk ingredient and one as bulk ingredient for human prescription compounding. There are no finished human gonadorelin products in the directory at all. Separately, gonadorelin acetate is carried on the FDA compounding document that sets out bulk drug substances for outsourcing facilities under section 503B, self-dated Updated March 21, 2025, in its category 1 heading "Bulk Drug Substances Under Evaluation", carrying the document's double-asterisk marker, which that document defines as designating bulk drug substances that are components of FDA-approved drugs. The same document's footnote states that FDA does not intend to take action against an outsourcing facility for failing to compound in accordance with section 503B(a)(5) if it fills orders for a compounded drug that is essentially a copy of an approved drug that has been discontinued and is no longer marketed — a sentence written for exactly the situation this compound is in.

Three further compounding determinations are worth stating precisely, because they are separate documents and are routinely conflated. Gonadorelin appears in no category of the corresponding 503A document, self-dated Updated May 14, 2026. It appears on neither of the two tables carried by FDA's separate web page on bulk drug substances for use in compounding that may present significant safety risks, content current as of 22 April 2026 — neither the table of bulk drug substances under category 2 of the interim policies, nor the table of bulk drug substances nominated but withdrawn. That places it in a materially different regulatory position from several peptides it is discussed beside, which do carry adverse FDA risk language on that page. None of this is an approval: a listing on a bulk-substances document is a fact about a nomination and an evaluation, and it is not an approval, not a compounding authorization, and not a safety clearance. Whether a discontinued-but-never-withdrawn approval satisfies the statutory compounding prong for a component of an approved drug is a question this page does not answer, because it could not be verified from a primary source.

Gonadorelin is separately and currently approved in US veterinary medicine, and that is not a human approval. Current federal animal-drug regulation describes gonadorelin injectable solutions in four specifications across five listed sponsor numbers, for the treatment of ovarian follicular cysts and for synchronizing estrous cycles in cattle, and restricts the drug by federal law to use by or on the order of a licensed veterinarian. One of those animal applications, NADA 139-237, carries the brand name FACTREL — the same brand name as the discontinued human application — which is why database searches for the human drug keep returning animal-drug rules.

Anti-doping status: named, and the scope clause is part of the fact. The 2026 World Anti-Doping Agency International Standard Prohibited List, in force from 1 January 2026, was retrieved on 1 September 2026 from the WADA-hosted document linked by the USADA prohibited-list page. On it, gonadorelin is named at S2.2.1, under the heading "Testosterone-stimulating peptides in males including, but not limited to:", in the bullet reading "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin)". The S2 class header states that the class is prohibited at all times, in- and out-of-competition, and that all prohibited substances in the class are non-Specified Substances. The heading's restriction — in males — is part of the entry and is transcribed here rather than paraphrased. Because gonadorelin is named in S2, section S0 does not reach it: S0 by its own terms covers only substances not addressed by any subsequent section of the List. Separately, the 2026 Monitoring Program, retrieved the same day, carries one peptide-hormone entry reading "In and Out-of-Competition: Gonadotrophin-releasing hormone (GnRH) analogues in females under 18 years only." Monitoring is not prohibition, and that entry names analogues in females under 18 — a different set and a different scope from the parent compound named at S2.2.1. The List is reissued annually and any athlete in a tested sport should confirm the current year's edition rather than rely on a static page.

Anything bearing the name in the United States therefore reaches a person through a prescriber and a compounding pharmacy, with no approved labeling behind it and no manufacturer post-marketing surveillance. Peptide Health Lab does not sell peptides, does not prescribe, and does not tell anyone where to obtain anything. One closing point of fact is worth keeping in view: the diagnostic stimulation test that the original 1982 approval was granted for is still performed and still reported in the current published literature.^[14][15]

Questions to bring to a provider

The gap between the population gonadorelin was studied in and the population asking about it is wide enough that the questions follow directly from the record:

• What is the goal — fertility, puberty induction, a diagnosis, or testosterone — and which of those does the published evidence actually address?^[3]
• Is there a documented deficiency of endogenous gonadotropin-releasing hormone here, and what testing established it?^[15]
• Given that every therapeutic regimen in the literature is a pump delivering a pulse every 90 minutes for months, what delivery pattern is being proposed and what result would show it is working?^[12][1]
• If fertility is the goal, how does this compare with combined gonadotropin therapy on the endpoints that were not significantly different — sperm detection rate, sperm concentration and pregnancy rate?^[3]
• If testosterone is the goal, how should the cohort finding of lower serum testosterone during pulsatile therapy than during gonadotropin therapy be weighed?^[5]
• What monitoring — gonadotropins, testosterone or oestradiol, semen analysis, ultrasound in women — is planned, and at what interval?^[11]
• What is the plan if an allergic or hypersensitivity reaction occurs, and where will the first administration take place?^[9]
• Given that the best available adverse-event frequencies come from a single 45-man series — gynecomastia in 8, subcutaneous induration in 6, allergic reaction in 3 — what is being watched for and how often?^[8]
• For a compounded preparation, what beyond-use date and handling instructions come with it, given that no current approved labeling exists?

The most accurate short summary a clinician can give is that this is pump therapy for people whose hypothalamus supplies no signal of its own, that the randomized evidence sits in ovulation induction, and that the question most people bring to it has never been put to a study.